SQZ, Roche expand deal to jointly develop cancer cell therapies

By Mark Zipkin | Oct 15, 2018 | 2:41 PM GMT

SQZ Biotechnologies Co. (Watertown, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) expanded a 2015 deal to co-develop and commercialize antigen presenting cell (APC) therapies to treat cancers that are difficult to address with other adoptive cell therapy strategies.